Setmelanotide

CHEMBL3301624 Phase 4 承認済み Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1117.3 g/mol

LogP

-2.5

Phase

4

Setmelanotide is a melanocortin-4 receptor (MC4R) agonist peptide used for chronic weight management in patients with obesity due to specific genetic deficiencies affecting the leptin-melanocortin pathway, including POMC, PCSK1, or LEPR deficiency. By activating MC4R in the hypothalamus, it restores impaired satiety signaling in patients with these rare monogenic obesity disorders, reducing appetite and promoting weight loss. It is the first approved therapy specifically targeting genetically defined melanocortin pathway deficiencies.

分子量

1117.3000 g/mol

LogP

-2.50

TPSA

500.00 Å²

リピンスキーの五則

不適合

治療領域

Obesity

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@@H](C)NC1=O

InChI

InChI=1S/C49H68N18O9S2/c1-26-41(70)63-37(20-30-22-55-25-59-30)46(75)64-35(18-28-10-4-3-5-11-28)44(73)62-34(15-9-17-57-49(53)54)43(72)65-36(19-29-21-58-32-13-7-6-12-31(29)32)45(74)66-38(40(50)69)23-77-78-24-39(47(76)60-26)67-42(71)33(61-27(2)68)14-8-16-56-48(51)52/h3-7,10-13,21-22,25-26,33-39,58H,8-9,14-20,23-24H2,1-2H3,(H2,50,69)(H,55,59)(H,60,76)(H,61,68)(H,62,73)(H,63,70)(H,64,75)(H,65,72)(H,66,74)(H,67,71)(H4,51,52,56)(H4,53,54,57)/t26-,33+,34+,35-,36+,37+,38+,39+/m1/s1

Molecular Formula

C49H68N18O9S2

HBD / HBA

15 / 14

回転可能結合数

18

重原子数

78

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

Setmelanotide is a melanocortin-4 receptor (MC4R) agonist peptide used for chronic weight management in patients with obesity due to specific genetic deficiencies affecting the leptin-melanocortin pathway, including POMC, PCSK1, or LEPR deficiency. By activating MC4R in the hypothalamus, it restores impaired satiety signaling in patients with these rare monogenic obesity disorders, reducing appetite and promoting weight loss. It is the first approved therapy specifically targeting genetically defined melanocortin pathway deficiencies.

Yes, Setmelanotide is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3301624. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 11993702. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Setmelanotide PillFYIで

構造

クイックデータ

分子式: C49H68N18O9S2
同義語: 1

外部リンク

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.